Principal InvestigatorJason D. Wright, MDA single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation.
Principal InvestigatorCarolyn L. Westhoff, MDTired of having to remember to take your birth control? If you are a woman between the ages of 18 and 35, are pre-menopausal, sexually active and do NOT wish to become pregnant, you are invited to see if you may qualify for a research study. The purpose of this research study is to test the effectiveness of an investigational contraceptive vaginal ring. If you qualify, you will receive investigational study medication, study-related medical exams, and laboratory services at no charge. You may also be reimbursed for time, travel, and other expenses.
Principal InvestigatorAna I. Tergas, MDThis research study is designed to see if olaparib is effective in treating high-grade epithelial ovarian,fallopian tube, or primary peritoneal cancer and whether it causes any side effects.A capsule formulation of olaparib (tradename Lynparza) is approved by the European Commission(EC), US Food and Drug Administration (FDA) and other countries for the treatment of advanced BRCA-mutated ovarian cancer in women.A tablet formulation of olaparib is being tested in this study.